Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: Systematic review of evidence, elicitation of subjective probabilities and economic modeling

Health Technology Assessment

Volumn 17, Issue 12, 2013, Pages 7-144

  Meads, C ^a   Auguste, P ^b   Davenport, C ^b   Malysiak S ^c   Sundar, S ^b   Kowalska, M ^c   Zapalska, A ^c   Guest, P ^d   Thangaratinam, S ^b   Martin Hirsch, P ^e   Borowiack, E ^c   Barton, P ^b   Roberts, T ^b   Khan, K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Arcana Institute   (Poland)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTICLE; ASYMPTOMATIC DISEASE; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS EXENTERATION; RADICAL HYSTERECTOMY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; COST BENEFIT ANALYSIS; ECONOMICS; HYSTERECTOMY; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REVIEW; SCINTISCANNING; STATISTICAL MODEL; STATISTICS; SURVIVAL; UNITED KINGDOM; UTERINE CERVIX TUMOR;

ASYMPTOMATIC DISEASES; CHEMORADIOTHERAPY; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; HYSTERECTOMY; MAGNETIC RESONANCE IMAGING; MODELS, ECONOMIC; PELVIC EXENTERATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SENSITIVITY AND SPECIFICITY; STATE MEDICINE; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 84876096985     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17120     Document Type: Article

References (155)

1. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009;105:103-104. http://dx.doi.org/10.1016/j.ijgo.2009.02.012
2. Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 1928;339:b2569. http://dx.doi.org/10.1136/bmj.b2569
3. Scottish Intercollegiate Guidelines Network. Management of cervical cancer. Guideline no. 99. Edinburgh: NHS Quality Improvement Scotland; 2008.
4. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 2008;97:989-991.
5. Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2007;100:1191-1197. http://dx.doi.org/10.1038/sj.bjc.6604974
6. Cancer Research UK. Cervical cancer - UK incidence statistics. URL: http://info.cancerresearchuk.org/cancerstats/types/cervix/incidence/ (accessed 16 January 2012).
7. Cancer Research UK. Cervical cancer - UK mortality statistics. URL: http://info.cancerresearchuk.org/cancerstats/types/cervix/mortality/ (accessed 16 January 2012).
8. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev 2009;18:792-800. http://dx.doi.org/10.1158/1055-9965.EPI-08-0965
9. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009;18:1060-1069. http://dx.doi.org/10.1158/1055-9965.EPI-08-1186
10. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609-1621. http://dx.doi.org/10.1016/S0140-6736(07)61684-5
11. Collins S, Rollason TP, Young LS, Woodman CB. Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study. Eur J Cancer 2010;46:405-411. http://dx.doi.org/10.1016/j.ejca.2009.09.015
12. Fujita M, Tase T, Kakugawa Y, Hoshi S, Nishino Y, Nagase S, et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. Tohoku J Exp Med 2008;216:297-307. http://dx.doi.org/10.1620/tjem.216.297
13. Holmes RS, Hawes SE, Toure P, Dem A, Feng Q, Weiss NS, et al. HIV infection as a risk factor for cervical cancer and cervical intraepithelial neoplasia in Senegal. Cancer Epidemiol Biomarkers Prev 2009;18:2442-2446. http://dx.doi.org/10.1158/1055-9965.EPI-08-0956
14. Cancer Research UK. Cervical cancer - risk factors. URL: http://info.cancerresearchuk.org/cancerstats/types/cervix/riskfactors/ (accessed 20 January 2012).
15. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781. http://dx.doi.org/10.1016/j.ejca.2009.12.014
16. Sundar S, Horne A, Kehoe S. Cervical cancer. Clinical Evid (Online) 2008. pii: 0818.
17. Anon. Topotecan (Hycamtin®) for the treatment of recurrent and stage IVB carcinoma of the cervix. Single Technology Appraisal (STA) submission to the National Institute for Health and Clinical Excellence. London: GlaxoSmithKline; 2009.
18. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 1999;73:177-183. http://dx.doi.org/10.1006/gyno.1999.5387
19. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
20. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529-534. http://dx.doi.org/10.1016/j.ygyno.2006.09.009
21. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187-193. http://dx.doi.org/10.1006/gyno.2000.5860
22. Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage cervical cancer in South Wales. BJOG 2004;111:1444-1448. http://dx.doi.org/10.1111/j.1471-0528.2004.00280.x
23. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Recurrent squamous cell carcinoma of the cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249-257. http://dx.doi.org/10.1016/j.ijrobp.2004.02.044
24. Kim M-K, Jo H, Kong H-J, Kim HC, Kim JW, Kim Y-M, et al. Postoperative nomogram predicting risk of recurrence after radical hysterectomy for early-stage cervical cancer. Int J Gynecol Cancer 2010;20:1581-1586.
25. Hirakawa M, Nagai Y, Inamine M, Ogawa K, Toita T, Murayama S, et al. Predictive factors of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 2008;108:126-129. http://dx.doi.org/10.1016/j.ygyno.2007.08.091
26. Gadducci A, Tana R, Fanucci A, Genazzani AR. Biochemical prognostic factors and the risk of relapses in patients with cervical cancer. Gynecol Oncol 2007;107:S23-S26. http://dx.doi.org/10.1016/j.ygyno.2007.07.033
27. American Cancer Society. Find support and treatment, the most reliable cancer treatment information. Staging. URL: www.cancer.org/Treatment/UnderstandingYourDiagnosis/staging (accessed January 2012).
28. Mabuchi S, Isohashi F, Yoshioka Y, Temma K, Takeda T, Yamamoto T, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer 2010;20:834-840. http://dx.doi.org/10.1111/IGC.0b013e3181dcadd1
29. Albon E, Tsourapas A, Frew E, Davenport C, Oyebode F, Bayliss S, et al. Structural neuroimaging in psychosis: a systematic review and economic evaluation. Health Technol Assess 2008;12(18).
30. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11(44).
31. Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 2008;110:S55-S59. http://dx.doi.org/10.1016/j.ygyno.2008.05.023
32. Salani R, Backes FJ, Fung Kee Fung M, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466-478. http://dx.doi.org/10.1016/j.ajog.2011.03.008
33. Barrington S, Scarsbrook A. Evidence based indications for the use of PET-CT in the United Kingdom 2012. London: Royal College of Physicians and Royal College of Radiologists; 2012.
34. Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDGPET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009;112:104-109. http://dx.doi.org/10.1016/j.ygyno.2008.08.028
35. Schwartz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2012;298:2289-2295. http://dx.doi.org/10.1001/jama.298.19.2289
36. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2009.
37. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2008. http://dx.doi.org/10.1002/9780470712184
38. Diagnostic Test Accuracy Working Group. Handbook for DTA reviews. URL: http://srdta.cochrane.org/handbook-dta-reviews (accessed January 2012).
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-1012. http://dx.doi.org/10.1016/j.jclinepi.2009.06.005
40. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2010;3:25. http://dx.doi.org/10.1186/1471-2288-3-25
41. Meads CA, Davenport CF. Quality assessment of diagnostic before-after studies: development of methodology in the context of a systematic review. BMC Med Res Methodol 2009;9:3. http://dx.doi.org/10.1186/1471-2288-9-3
42. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-251. http://dx.doi.org/10.1093/biostatistics/kxl004
43. Reitsma JB, Glas AS, Rutges AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-990. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022
44. O'Hagan A, Buck CE, Daneschkkah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain judgements: eliciting expert's probabilities. Chichester, UK: Wiley-Blackwell; 2006. http://dx.doi.org/10.1002/0470033312
45. Moons KG, Harrell FE. Sensitivity and specificity should be de-emphasized in diagnostic accuracy studies. Acad Radiol 2003;10:670-672. http://dx.doi.org/10.1016/S1076-6332(03)80087-9
46. Davenport CF. Systematic reviews of test accuracy: developing methods that meet practitioners' needs. PhD thesis. Birmingham: University of Birmingham; 2012.
47. National Institute for Health and Clinical Excellence. Methods for the development of NICE public health guidance. 2nd edn. London: NICE; 2009.
48. Amit A, Beck D, Lowenstein L, Lavie O, Bar S, Kedar Z, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006;100:65-69. http://dx.doi.org/10.1016/j.ygyno.2005.07.013
49. Grisaru D, Almog B, Levine C, Metser U, Fishman A, Lerman H, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol 2004;94:680-684. http://dx.doi.org/10.1016/j.ygyno.2004.05.053
50. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET-CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 2008;18:2040-2047. http://dx.doi.org/10.1007/s00330-008-0979-9
51. Mittra E, El-Maghraby T, Rodriguez CA, Quon A, Ross McDougal I, Gambhir SS, et al. Efficacy of 18F-FDG PET-CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1952-1959. http://dx.doi.org/10.1007/s00259-009-1206-x
52. Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, et al. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007;34:472-479. http://dx.doi.org/10.1007/s00259-006-0251-y
53. Hatano K, Sekiya Y, Araki H, Sakai M, Togawa T, Narita Y, et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1999;45:639-664. http://dx.doi.org/10.1016/S0360-3016(99)00228-X
54. Weber TM, Sostman HD, Spritzer CE, Ballard RL, Meyer GA, Clarke-Pearson DL, et al. Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology 1995;194:135-139.
55. Heron CW, Husband JE, Williams MP, Dobbs J, Cosgrove DO. The value of CT in the diagnosis of recurrent carcinoma of the cervix. Clin Radiol 1988;39:501. http://dx.doi.org/10.1016/S0009-9260(88)80211-3
56. Park DH, Kim KH, Park SY, Lee BH, Choi CW, Chin SY. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography. Korean J Radiol 2000;1:51-55. http://dx.doi.org/10.3348/kjr.2000.1.1.51
57. Walsh JW, Amendola MA, Hall DJ, Tisnado J, Goplerud DR. Recurrent carcinoma of the cervix: CT diagnosis. AJR Am J Roentgenol 1981;136:117-122.
58. Williams MP, Husband JE, Heron CW, Cherryman GR, Koslin DB. Magnetic resonance imaging in recurrent carcinoma of the cervix. Br J Radiol 1989;62:544-550. http://dx.doi.org/10.1259/0007-1285-62-738-544
59. Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic or persistent cervical cancer: a systematic review. Int J Gynecol Cancer 2007;17:1194-1204. http://dx.doi.org/10.1111/j.1525-1438.2007.00900.x
60. Alberts DS, Kronmal R, Baker LH, Stock-Novack DL, Surwit EA, Boutselis JG, et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 1987;5:1791-1795
61. Barlow JJ, Piver MS, Chuang JT, Cortes EP, Onuma T, Holland JF. Adriamycin and bleomycin, alone and in combination, in gynecologic cancers. Cancer 1973;32:735-773. http://dx.doi.org/10.1002/1097-0142(197310)32:4735::AID-CNCR28203204013.0.CO;2-K
62. Bezwoda WR, Nissenbaum M, Derman DP. Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate. Med Pediatr Oncol 1986;14:17-19. http://dx.doi.org/10.1002/mpo.2950140105
63. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002;20: 1832-1833 http://dx.doi.org/10.1200/JCO.2002.07.045
64. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-1085.
65. Cadron I, Jakobsen A, Vergote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. Gynecol Obstet Invest 2005;59:126-129
66. Garin A, Moiseyenko VM, Roszak A, Valvere V, El Gueddari B, Fumoleau P, et al. Randomised Phase II study of irinotecan or irinotecan in combination with cisplatinum or cisplatinum in first line in patients with metastatic squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 2001;20:abstract 826.
67. Greenberg BR, Kardinal CG, Pajak TF, Bateman JR. Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treat Rep 1977;61:1383-1388
68. Lira-Puerto V, Silva A, Morris M, Martinez R, Groshen S, Morales-Canfield F, et al. Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol 1991;28:391-396 http://dx.doi.org/10.1007/BF00685695
69. Grendys EC Jr, Long HJ, Bundy BN, Benda J, McMeekin DS, Sorosky JI, et al. Randomized phase III trial of cisplatin vs cisplatin plus topotecan vs the combination of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2004:14(Suppl. 1):12.
70. Long HJ, Bundy BN, Grendys EC Jr, Benda J, McMeekin DS, Sorosky JAU, et al. Randomized phase III trial of cisplatin vs cisplatin plus topotecan vs MVAC in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004:92:397.
71. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-4646. http://dx.doi.org/10.1200/JCO.2005.10.021
72. Monk BJ, Huang H, Cella D, Long HJ. Quality of life outcomes from GOG 179: a phase III trial of cisplatin vs cisplatin/topotecan in recurrent or persistent carcinoma of the cervix. Int J Gynecol Cancer 2004:14(Suppl. 1):42.
73. Monk BJ, Huang HQ, Cella D, Long IIIH, Mackey D. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4617-4625. http://dx.doi.org/10.1200/JCO.2005.10.522
74. McGuire WP III, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462-1468.
75. Monk BJ, Mas LL, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-3569. http://dx.doi.org/10.1200/JCO.2009.26.9571
76. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boar dman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-4655. http://dx.doi.org/10.1200/JCO.2009.21.8909
77. McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:296-304. http://dx.doi.org/10.1016/j.ygyno.2005.10.039
78. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-3119. http://dx.doi.org/10.1200/JCO.2004.04.170
79. Mountzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, et al. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2009;20:1362-1368. http://dx.doi.org/10.1093/annonc/mdn797
80. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-171.
81. Thomsen TK, Pfeiffer P. Teniposide or carboplatin in patients with recurrent or advanced cervical carcinoma: a randomized phase II trial. Int J Gynecol Cancer 1998;8:310-314. http://dx.doi.org/10.1046/j.1525-1438.1998.09811.x
82. Vermorken JB, Zanetta G, de Oliveira CF, van der Burg ME, Lacave AJ, Teodorovic I, et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol 2001;12:967-974. http://dx.doi.org/10.1023/A:1011165115426
83. Wallace HJ Jr, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler WC Jr, Blessing JA. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 1978;62:1435-1441.
84. Ciatto S, Pirtoli L, Cionini L. Radiotherapy for postoperative failures of carcinoma of the cervix uteri. Surg Gynecol Obstet 1980;151:621-624.
85. Deutsch M, Parsons JA. Radiotherapy for carcinoma of the cervix recurrent after surgery. Cancer 1974;34:2051-2055. http://dx.doi.org/10.1002/1097-0142(197412)34:62051::AID-CNCR28203406253.0.CO;2-G
86. Hille A, Weiss E, Hess CF. Therapeutic outcome and prognostic factors in the radiotherapy of recurrences of cervical carcinoma following surgery. Strahlenther Onkol 2003;179:742-747. http://dx.doi.org/10.1007/s00066-003-1100-6
87. Ito H, Shigematsu N, Kawada T, Kubo A, Isobe K, Hara R, et al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 1997;67:154-161. http://dx.doi.org/10.1006/gyno.1997.4855
88. Jain P, Hunter RD, Livsey JE, Coyle C, Swindell R, Davidson SE. Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer. Clin Oncol 2007;19:763-768. http://dx.doi.org/10.1016/j.clon.2007.08.015
89. Jobsen JJ, Leer JW, Cleton FJ, Hermans J. Treatment of locoregional recurrence of carcinoma of the cervix by radiotherapy after primary surgery. Gynecol Oncol 1989;33:368-371. http://dx.doi.org/10.1016/0090-8258(89)90529-5
90. Lucraft HH. Radiotherapy following primary surgery for carcinoma of uterine cervix. Clin Radiol 1981;32:347-353. http://dx.doi.org/10.1016/S0009-9260(81)80062-1
91. Potter ME, Alvarez RD, Gay FL, Shingleton HM, Soong SJ, Hatch KD. Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol 1990;37:74-77. http://dx.doi.org/10.1016/0090-8258(90)90311-8
92. Tan R, Chung CH, Liu MT, Lai YL, Chang KH. Radiotherapy for postoperative recurrent uterine cervical carcinoma. Acta Oncol 1991;30:353-356. http://dx.doi.org/10.3109/02841869109092385
93. Grigsby PW. Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy. Int J Gynecol Cancer 2004;14:860-864. http://dx.doi.org/10.1111/j.1048-891X.2004.14521.x
94. Haasbeek CJA, Uitterhoeve ALJ, van der Velden J, Gonzalez DG, Stalpers LJA. Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 2008;89:197-204. http://dx.doi.org/10.1016/j.radonc.2008.01.004
95. Ijaz T, Eifel PJ, Burke T, Oswald MJ. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol 1998;70:241-246. http://dx.doi.org/10.1006/gyno.1998.5093
96. Maneo A, Landoni F, Cormio G, Colombo A, Placa F, Pellegrino A, et al. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol 1999;10:803-807. http://dx.doi.org/10.1023/A:1008356010556
97. Thomas GM, Dembo AJ, Black B, Bean HA, Beale FA, Pringle JR, et al. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. Gynecol Oncol 1987;27:254-260. http://dx.doi.org/10.1016/0090-8258(87)90243-5
98. Tsuda H, Tanaka M, Manabe T, Ikeda H, Negoro S, Ishiko O, et al. Phase I study of combined radiation, hyperthermia and intra-arterial carboplatin for local recurrence of cervical cancer. Ann Oncol 2003;14:298-303. http://dx.doi.org/10.1093/annonc/mdg054
99. Virostek LJ, Kim RY, Spencer SA, Meredith RF, Jennelle RL, Soong SJ, et al. Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation therapy options. Radiology 1996;201:559-563.
100. Adcock LL. Radical hysterectomy preceded by pelvic irradiation. Gynecol Oncol 1979;8:152-163. http://dx.doi.org/10.1016/0090-8258(79)90020-9
101. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 1994;55:29-35. http://dx.doi.org/10.1006/gyno.1994.1242
102. Ibsen TB, Sorensen BL, Knudsen JB, Sorensen HM. Operative treatment of recurrent cancer of the uterine cervix after radiotherapy. Acta Obst Gynecol Scand 1988;67:389-393. http://dx.doi.org/10.3109/00016348809004245
103. Maneo A, Landoni F, Cormio G, Colombo A, Mangioni C. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer 1999;9:295-301. http://dx.doi.org/10.1046/j.1525-1438.1999.99037.x
104. Rubin SC, Hoskins WJ, Lewis JLJ. Radical hysterectomy for recurrent cervical cancer following radiation therapy. Gynecol Oncol 1987;27:316-324. http://dx.doi.org/10.1016/0090-8258(87)90252-6
105. Terada K, Morley GW. Radical hysterectomy as surgical salvage therapy for gynecologic malignancy. Obstet Gynecol 1987;70:913-915.
106. Tupper C. Radical Wertheim as a salvage procedure. Patients with recurrence following initial definitive radiotherapy. Am J Obstet Gynecol 1965;91:364-368.
107. Anthopoulos AP, Manetta A, Larson JE, Podczaski ES, Bartholomew MJ, Mortel R. Pelvic exenteration: a morbidity and mortality analysis of a seven-year experience. Gynecol Oncol 1989;35:219-223. http://dx.doi.org/10.1016/0090-8258(89)90047-4
108. Barber HR, Jones W. Lymphadenectomy in pelvic exenteration for recurrent cervix cancer. JAMA 1971;215:1945-1949. http://dx.doi.org/10.1001/jama.1971.03180250037008
109. Beitler JJ, Anderson PS, Wadler S, Runowicz CD, Hayes MK, Fields AL, et al. Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival? Int J Radiat Oncol Biol Phys 1997;38:143-148. http://dx.doi.org/10.1016/S0360-3016(96)00585-8
110. Bricker EM, Butcher J, Lawler J, McAfee CA. Surgical treatment of advanced and recurrent cancer of the pelvic viscera: an evaluation of ten years' experience. Ann Surg 1960;152:388-401. http://dx.doi.org/10.1097/00000658-196009000-00004
111. Brunschwig A, Daniel W. Pelvic exenteration operations: with summary of sixty-six cases surviving more than five years. Ann Surg 1960;151:571-576. http://dx.doi.org/10.1097/00000658-196004000-00018
112. Chung CK, Nahhas WA, Stryker JA, Mortel R. Treatment outcome of recurrent cervical cancer. J Surg Oncol 1983;24:5-10. http://dx.doi.org/10.1002/jso.2930240103
113. Deckers PJ, Sugarbaker EV, Pilch YH, Ketcham AS. Pelvic exenteration for late second cancers of the uterine cervic after earlier irradiation. Ann Surg 1972;175:48-54. http://dx.doi.org/10.1097/00000658-197201000-00008
114. Hatch KD, Gelder MS, Soong SJ, Baker VV, Shingleton HM. Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol 1990;38:462-467. http://dx.doi.org/10.1016/0090-8258(90)90092-Y
115. Ketcham AS, Deckers PJ, Sugarbaker EV, Hoye RC, Thomas LB, Smith RR. Pelvic exenteration for carcinoma of the uterine cervix. A 15-year experience. Cancer 1970;26:513-521. http://dx.doi.org/10.1002/1097-0142(197009)26:3513::AID-CNCR28202603043.0.CO;2-6
116. Kraybill WG, Lopez MJ, Bricker EM. Total pelvic exenteration as a therapeutic option in advanced malignant disease of the pelvis. Surg Gynecol Obstet 1988;166:259-263.
117. Mikuta JJ, Murphy JJ. The team approach to pelvic exenteration for cervical cancer. Am J Obstet Gynecol. 1960;80:795-801.
118. Mikuta JJ, Murphy JJ, Schoenberg HW. Pelvic exenteration for cervical cancer. Obstet Gynecol 1967;29:858-861.
119. Palmer AB, Blaikley JB. Discussion on pelvic exenteration. Proc R Soc Med 1953;46:753-768.
120. Pinelo S, Petiz A, Domingues C, Lopes C, Alves A, Fael R. [Pelvic exenterations for gynaecological cancer - a 10 year institutional review.] Acta Med Port 2002;19:99-104.
121. Rutledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881-892.
122. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JMJ. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989;73:1027-1034. http://dx.doi.org/10.1097/00006250-198906000-00024
123. Stanhope CR, Webb MJ, Podratz KC. Pelvic exenteration for recurrent cervical cancer. Clin Obstet Gynecol 1990;33:897-909. http://dx.doi.org/10.1097/00003081-199012000-00026
124. Symmonds RE, Pratt JH, Webb MJ. Exenterative operations: experience with 198 patients. Am J Obstet Gynecol 1975;121:907-918.
125. Teran-Porcayo MA, Zeichner-Gancz I, del-Castillo RA, Beltran-Ortega A, Solorza-Luna G. Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico. Med Oncol 2006;23:219-223. http://dx.doi.org/10.1385/MO:23:2:219
126. Vieira SC, Costa DR, Meneses AD, Borges e Silva J, Oliveira AK, Sousa RB. [Post-radiotherapy pelvic exenteration in relapsed cervical cancer: experience of a tertiary health service in the northeast of Brazil.] Rev Bras Ginecol Obstet 2009;31:22-27. http://dx.doi.org/10.1590/S0100-72032009000100005
127. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnson D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-972. http://dx.doi.org/10.1200/JCO.20.4.966
128. Bliss P, Trott PA, Blake PR. Cost-effectiveness of routine cytological cervical surveillance following treatment for carcinoma of the cervix. J Clin Effect 1997;2:87-90.
129. Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002;84:7-11. http://dx.doi.org/10.1006/gyno.2001.6497
130. Forni F, Ferrandina G, Deodato F, Macchia G, Morganti AG, Smaniotto D, et al. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys 2007;69:1145-1149. http://dx.doi.org/10.1016/j.ijrobp.2007.04.055
131. Manusirivithaya S, Sripramote M, Tangjitgamol S, Sanjareonsuttikul N, Pisamturakit P. Cost effectiveness of concurrent chemoradiation in comparison with radiation alone in locally advanced cervical cancer. J Med Assoc Thail 2005;88:1035-1044.
132. Melnikow J, Kulasingam S, Slee C, Helms J, Kuppermann M, Birch S, et al. Surveillance after treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2010;116:1158-1170. http://dx.doi.org/10.1097/AOG.0b013e3181f88e72
133. Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, et al. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technol Assess 2010;14(Suppl. 1):55-62.
134. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Dec Making 1993;13:332-338. http://dx.doi.org/10.1177/0272989X9301300409
135. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-540. http://dx.doi.org/10.1016/S0140-6736(97)02250-2
136. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 1999;340:1154-1161. http://dx.doi.org/10.1056/NEJM199904153401503
137. Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin Oncol 2010;22:590-601. http://dx.doi.org/10.1016/j.clon.2010.06.002
138. Adriano E, Jagoe J, Harrison T, Riffenburgh RH, Johnstone PA. Survival of patients with untreated cervical carcinoma. Am J Clin Oncol 2003;26:369-373. http://dx.doi.org/10.1097/01.COC.0000026909.73608.88
139. Department of Health (DoH). NHS reference costs 2009-10. London: DoH; 2011.
140. Clark J, Barton P, Gupta J, Khan K. Outpatient diagnosis of endometrial cancer in women with first episode of postmenopausal bleeding. Report no. 51. Birmingham: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham; 2002.
141. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
142. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2011;15(35).
143. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch X, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615. http://dx.doi.org/10.1093/jnci/djh104
144. Lang H-C, Chang K, Ying Y-H. Quality of life, treatments, and patients' willingness to pay for a complete remission of cervical cancer in Taiwan [published online ahead of print 9 September 2011]. Health Econ 2011.
145. Tewari K, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005;7:419-434. http://dx.doi.org/10.1007/s11912-005-0007-z
146. Tzioras S, Pavlidis N, Paraskevaidis E, Ioannidis JP. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev 2007;33:24-38. http://dx.doi.org/10.1016/j.ctrv.2006.09.007
147. Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta-analysis. Clin Oncol 2002;14:203-212. http://dx.doi.org/10.1053/clon.2002.0076
148. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007;11(50).
149. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carvinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:903. http://dx.doi.org/10.1002/1097-0142(19810815)48:4899::AID-CNCR28204804063.0.CO;2-6
150. Lira-Puerto V, de la Huerta R, Cortes H, Fernandez A, Silva A, Martinez R, et al. Cisplatin (CDDP) plus radiotherapy (RT) vs radiotherapy alone in locally advanced cervical cancer. Proc Am Soc Clin Oncol 1990;9:abstract 633.
151. Pearcey R, Brundage M, Jeffrey J. A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 2000;19:abstract 378a.
152. Chiara S, Bruzzone M, Merlini L, Bruzzi P, Rosso R, Franzone P, et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North West Oncologic Cooperative Group). Am J Clin Oncol 1994;17:294-297. http://dx.doi.org/10.1097/00000421-199408000-00003
153. Choo YC, Choy TK, Wong LC, Ma HK. Potentiation of radiotherapy by cis-dichlorodiammine platinum (II) in advanced cervical carcinoma. Gynecol Oncol 1986;23:94-100. http://dx.doi.org/10.1016/0090-8258(86)90120-4
154. Garipagaoglu M, Kayikcioglu F, Kose MF, Adli M, Gulkesen KH, Kocak Z, et al. Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma: a prospective randomised pilot study. Br J Radiol 2004;77:581-587. http://dx.doi.org/10.1259/bjr/63967203
155. Wong LC, Choo YC, Choy D, Sham JS, Ma HK. Long term follow up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol Oncol 1989;35:159-163. http://dx.doi.org/10.1016/0090-8258(89)90035-8